- $2.55bn
- $2.14bn
- $517.15m
- 93
- 44
- 46
- 66
Annual income statement for Veracyte, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 220 | 297 | 361 | 446 | 517 |
| Cost of Revenue | |||||
| Gross Profit | 145 | 195 | 248 | 298 | 363 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 301 | 338 | 447 | 430 | 459 |
| Operating Profit | -81.9 | -41.1 | -85.8 | 16.1 | 57.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -81.6 | -36.4 | -76.6 | 25.7 | 68.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -75.6 | -36.6 | -74.4 | 24.1 | 66.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -75.6 | -36.6 | -74.4 | 24.1 | 66.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -75.6 | -36.6 | -74.4 | 24.1 | 66.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.901 | -0.481 | -0.413 | 0.349 | 1.07 |